IL264141B - Novel heteroaromatic modulators of retinoid-related orphan gamma receptor - Google Patents

Novel heteroaromatic modulators of retinoid-related orphan gamma receptor

Info

Publication number
IL264141B
IL264141B IL264141A IL26414119A IL264141B IL 264141 B IL264141 B IL 264141B IL 264141 A IL264141 A IL 264141A IL 26414119 A IL26414119 A IL 26414119A IL 264141 B IL264141 B IL 264141B
Authority
IL
Israel
Prior art keywords
retinoid
modulators
receptor gamma
orphan receptor
related orphan
Prior art date
Application number
IL264141A
Other languages
English (en)
Hebrew (he)
Other versions
IL264141A (en
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Publication of IL264141A publication Critical patent/IL264141A/en
Publication of IL264141B publication Critical patent/IL264141B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
IL264141A 2016-07-13 2019-01-08 Novel heteroaromatic modulators of retinoid-related orphan gamma receptor IL264141B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16020268 2016-07-13
PCT/EP2017/067390 WO2018011201A1 (en) 2016-07-13 2017-07-11 Heteroaromatic modulators of the retinoid-related orphan receptor gamma

Publications (2)

Publication Number Publication Date
IL264141A IL264141A (en) 2019-02-28
IL264141B true IL264141B (en) 2021-09-30

Family

ID=56511303

Family Applications (1)

Application Number Title Priority Date Filing Date
IL264141A IL264141B (en) 2016-07-13 2019-01-08 Novel heteroaromatic modulators of retinoid-related orphan gamma receptor

Country Status (21)

Country Link
US (2) US10662181B2 (cg-RX-API-DMAC7.html)
EP (1) EP3484880B1 (cg-RX-API-DMAC7.html)
JP (1) JP7016344B2 (cg-RX-API-DMAC7.html)
KR (1) KR102490140B1 (cg-RX-API-DMAC7.html)
CN (1) CN109476653B (cg-RX-API-DMAC7.html)
AU (1) AU2017294969B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019000486A2 (cg-RX-API-DMAC7.html)
CA (1) CA3030370A1 (cg-RX-API-DMAC7.html)
DK (1) DK3484880T3 (cg-RX-API-DMAC7.html)
ES (1) ES2834009T3 (cg-RX-API-DMAC7.html)
IL (1) IL264141B (cg-RX-API-DMAC7.html)
MX (1) MX383770B (cg-RX-API-DMAC7.html)
MY (1) MY196990A (cg-RX-API-DMAC7.html)
PL (1) PL3484880T3 (cg-RX-API-DMAC7.html)
PT (1) PT3484880T (cg-RX-API-DMAC7.html)
RU (1) RU2771280C2 (cg-RX-API-DMAC7.html)
SA (1) SA519400868B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201811107WA (cg-RX-API-DMAC7.html)
UA (1) UA123330C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018011201A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201808436B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2771280C2 (ru) * 2016-07-13 2022-04-29 Лео Фарма А/С Гетероароматические модуляторы ретинол-связанного орфанного рецептора гамма
CN111825654A (zh) * 2019-04-19 2020-10-27 北京酷瓴生物技术有限公司 苯甲烯哌啶衍生物及其制备方法、中间体和用途
CN112898292A (zh) * 2019-12-03 2021-06-04 微境生物医药科技(上海)有限公司 新型极光激酶抑制剂及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS244821B2 (en) * 1983-06-16 1986-08-14 Boehringer Ingelheim Ltd Production method of new substituted phenylalkyl(piperazinyl or homopiperazinyle)-prpylureas or thioureas
WO2004073612A2 (en) 2003-02-13 2004-09-02 Merck & Co. Inc. Estrogen receptor modulators
FR2879381B1 (fr) 2004-12-15 2008-12-26 Thales Sa Systeme de distribution quantique de cle de cryptage a variables continues
MX2007012392A (es) * 2005-04-04 2007-12-05 Ab Science Derivados de oxazol sustituidos y su uso como inhibidores de tirosina cinasa.
EP2511275A1 (en) 2011-04-12 2012-10-17 Bioprojet Novel piperidinyl monocarboxylic acids as S1P1 receptor agonists
SI2928885T1 (sl) * 2012-12-06 2017-06-30 Glaxo Group Limited Modulatorji retinoidnemu sorodnega receptorja gama sirote (ror-gama) za uporabo pri zdravljenju avtoimunskih in vnetnih bolezni
WO2015067575A1 (en) * 2013-11-05 2015-05-14 F. Hoffmann-La Roche Ag 5,6,7,8-tetrahydro-5,8-methanocinnoline derivatives as rorc modulators for the treatment of autoimmune diseases
WO2015180613A1 (en) * 2014-05-28 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Novel compounds
WO2015180612A1 (en) 2014-05-28 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Novel compounds
ES2716966T3 (es) * 2014-05-28 2019-06-18 Glaxosmithkline Ip Dev Ltd Derivados de piperazina como moduladores de ROR-gamma
RU2771280C2 (ru) * 2016-07-13 2022-04-29 Лео Фарма А/С Гетероароматические модуляторы ретинол-связанного орфанного рецептора гамма

Also Published As

Publication number Publication date
UA123330C2 (uk) 2021-03-17
RU2771280C2 (ru) 2022-04-29
US20190284177A1 (en) 2019-09-19
CA3030370A1 (en) 2018-01-18
US20200291010A1 (en) 2020-09-17
US10934282B2 (en) 2021-03-02
AU2017294969B2 (en) 2021-03-25
ZA201808436B (en) 2020-05-27
ES2834009T3 (es) 2021-06-16
SA519400868B1 (ar) 2022-06-13
MX383770B (es) 2025-03-14
PL3484880T3 (pl) 2021-04-06
PT3484880T (pt) 2020-12-07
RU2019103883A (ru) 2020-08-13
NZ749301A (en) 2021-03-26
US10662181B2 (en) 2020-05-26
EP3484880B1 (en) 2020-09-02
JP2019521137A (ja) 2019-07-25
JP7016344B2 (ja) 2022-02-04
IL264141A (en) 2019-02-28
MY196990A (en) 2023-05-17
SG11201811107WA (en) 2019-01-30
CN109476653A (zh) 2019-03-15
WO2018011201A1 (en) 2018-01-18
KR20190026872A (ko) 2019-03-13
CN109476653B (zh) 2022-04-22
RU2019103883A3 (cg-RX-API-DMAC7.html) 2020-09-23
BR112019000486A2 (pt) 2019-04-24
MX2019000361A (es) 2019-05-23
EP3484880A1 (en) 2019-05-22
AU2017294969A1 (en) 2019-01-17
KR102490140B1 (ko) 2023-01-19
DK3484880T3 (da) 2020-11-09

Similar Documents

Publication Publication Date Title
IL290153A (en) Tetrahydroquinolinone compounds are installed such as gamma modulators
IL263878A (en) Compounds as modulators of gamma ror
ZA201800506B (en) Novel compounds as ror gamma modulators
ZA201800827B (en) Substituted 4-azaindoles and their use as glun2b receptor modulators
EP3186225A4 (en) Cannabinoid type 1 receptor modulators
HUE051395T2 (hu) Heteroaromás NMDA receptor modulátorok és alkalmazásaik
ME03379B (me) Pozitivni alosterni modulatori muskarinskog m1 receptora
ZA201808436B (en) Heteroaromatic modulators of the retinoid-related orphan receptor gamma
IL271332B (en) Tetrahydropyridopyrazine modulators of gpr6
GB201616072D0 (en) Receptor modulator compounds
GB201616071D0 (en) Receptor modulator compounds
GB201616065D0 (en) Receptor modulator compounds
HK40007680A (en) N-carboxyanhydride-based-scale synthesis of elamipretide